Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
5-Year Cancer Survival Rate Rises 0.3 Point to 66.4%: NCC
The five-year relative cancer survival rate stood at 66.4% for patients diagnosed with the disease in Japan in 2010-2011, up 0.3 point from 2009-2010, according to data issued by the National Cancer Center (NCC) on December 14. The relative survival…
To read the full story
Related Article
- 5-Year Cancer Survival Rates Up 2 Points to 64.1%: NCC
April 17, 2020
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
ACADEMIA
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
- NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…